hiv care in new york state - linkage to care and viral ... · new york state methods for counting...

HIV Care in New York State, 2016:

Linkage to Care and Viral Suppression

Among Persons Residing in New York State

AIDS Institute

New York State Department of Health

Updated December 2017 2

Table of Contents Executive Summary ........................................................................................................................ 3

Major Findings .......................................................................................................................................... 4

Linkage to Care ..................................................................................................................................... 4

Any HIV Care ....................................................................................................................................... 4

Viral Suppression .................................................................................................................................. 4

Changes to the 2016 Report ...................................................................................................................... 4

Introduction ..................................................................................................................................... 5

Need for Assessing Engagement in HIV Care .......................................................................................... 5

Measures for Assessing Engagement in Care ........................................................................................... 5

New York State Results ............................................................................................................................ 6

New York State HIV Care Outcome Measures .............................................................................. 7

Linkage to Care after Diagnosis (Appendix Table A) .............................................................................. 7

Measures of Care (Appendix Table B) ..................................................................................................... 8

Viral Suppression (Appendix Table C) ..................................................................................................... 9

New York State and the NHAS Targets ....................................................................................... 10

Linkage to Care ....................................................................................................................................... 10

Continuous Care...................................................................................................................................... 10

Viral Suppression .................................................................................................................................... 10

Increasing Linkage and Retention in Care .............................................................................................. 10

Technical Notes and Appendices .................................................................................................. 11

Contact Information ................................................................................................................................ 11

Data sources for calculation of HIV care measures ................................................................................ 11

Persons living with diagnosed HIV residing in NYS at the end of 2016 ................................................ 11

Calculation of NYS Cascade measures ................................................................................................... 12

Identification of incarcerated individuals ............................................................................................... 13

Table A: Entry to Care in 2016 Persons Newly Diagnosed with HIV, NYS, 2016 ..................... 14

Table B: Measures of Care in 2016 Persons Living with Diagnosed HIV in Dec. 2015 and Alive

in Dec. 2016, NYS ........................................................................................................................ 15

Table C: Viral Suppression in 2016 Persons Living with Diagnosed HIV in Dec. 2015 and Alive

in Dec. 2016, NYS ........................................................................................................................ 16


Executive Summary

The attached report presents summary measures of linkage to HIV medical care, engagement in

care and HIV viral suppression among persons living with diagnosed HIV (PLWDH) in New

York State (NYS). HIV care measures were calculated using data from the New York State

Department of Health (NYSDOH) HIV surveillance registry.

The Cascade presents a picture of the total HIV population at one point in time, across the

spectrum of the continuum of care from transmission through diagnosis, participation in care,

and success of care.


Major Findings

Linkage to Care

• In 2016, 75% of newly diagnosed persons in NYS showed evidence of entry to care

within 30 days of diagnosis. This percentage is below the 2020 National HIV/AIDS

Strategy (NHAS) target of 85% and the 2020 NYS Ending the Epidemic target of

90%, but is comparable to the United States (U.S.) 2015 average (75%).1,2

• In 2016, 87% of newly diagnosed cases in NYS showed evidence of entry to care

within 91 days of diagnosis. This compares well to the U.S. 2015 average (84%).1

Any HIV Care

• In 2016, 80% of PLWDH in NYS showed evidence of some care during the year.

Continuous care (≥2 visits/year, ≥91 days apart) was observed for 66% of PLWDH.

This percentage is lower than the 2020 NHAS target (90%).

• In the U.S. in 2014, 73% of PLWDH had any evidence of care and 57% were in

continuous care.1

Viral Suppression

• In 2016, 70% of PLWDH in NYS appeared to be virally suppressed. This percentage

is lower than the 2020 NHAS target (80%) and the 2020 NYS Ending the Epidemic

target (85%).2 In the U.S. in 2014, 58% of PLWDH appeared to be virally

suppressed.1

• In NYS, 59% of youth (aged 13-24 years) appeared to be virally suppressed in 2016.

This is lower than the 2020 NHAS target of 80%. In the U.S. in 2014, 48% of youth

(aged 13-24 years) appeared to be virally suppressed.1

• In NYS, 69% of persons with a history of injection drug use as the HIV transmission

risk appeared to be virally suppressed in 2016. This is lower than the 2020 NHAS

target of 80%. In the U.S. in 2014, 50% of persons with a history of injection drug

use as the HIV transmission risk appeared to be virally suppressed.1

Changes to the 2016 Report

The bar representing cases with continuous care during the year was removed from the 2016

cascade. The data behind this measure are still presented in Table B of this report.

1 Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by

using HIV surveillance data—United States and 6 dependent areas, 2015. HIV Surveillance Supplemental Report

2017;22(No. 2). http://www.cdc.gov/hiv/library/reports/hivsurveillance.html. Published July 2017. Accessed

[11/2017]. 2 Ending the Epidemic in New York State. http://www.health.ny.gov/diseases/aids/ending_the_epidemic/index.htm

http://www.health.ny.gov/diseases/aids/ending_the_epidemic/index.htm

Introduction

Need for Assessing Engagement in HIV Care

In 2014, the Governor of New York outlined the Ending the Epidemic (ETE) initiative to end the

AIDS epidemic in NYS. As part of the three-point plan, increased efforts are being directed

towards: 1) identifying persons with HIV who remain undiagnosed and getting them linked to

care; 2) linking and retaining persons diagnosed with HIV in healthcare to maximize viral

suppression; and 3) increasing access to Pre-Exposure Prophylaxis (PrEP) for HIV negative

persons.

The provision of appropriate medical care for PLWDH is a key feature of the ETE initiative and

the NHAS. In addition to the immediate benefit to the PLWDH, persons retained in successful

treatment for their HIV diagnosis who have achieved and maintained undetectable viral loads are

effectively not able to sexually transmit the virus to others. The HIV care cascade is one tool for

assessing the extent and effectiveness of HIV-related medical care in NYS.

Measures for Assessing Engagement in Care

The NHAS, originally released in 2010, outlined a set of targets for the nation’s fight against

HIV/AIDS. The document called for an increase in the percentage of persons with timely linkage

to care, retention in care and HIV viral suppression. Retention in care and viral suppression

targets were defined for specific subpopulations and Ryan White program clients but were

applied to the total NYS population of PLWDH. The targets were:

1. Increase the percentage of newly diagnosed patients linked to care within three

months of diagnosis to 85%.

2. Increase the percentage of PLWDH who are in continuous care, defined as ≥2

visits/year, separated by ≥3 months to 80%.

3. Increase the percentage of PLWDH with undetectable viral load by 20%.

The 2015 update of the NHAS report revised the indicators and set targets for 2020. The 2020

targets for linkage to care, retention in care and viral suppression are:

1. Increase the percentage of newly diagnosed persons linked to HIV medical care

no more than one month of HIV diagnosis to at least 85%.

2. Increase the percentage of persons with diagnosed HIV who are retained in care

to at least 90%.

3. Increase the percentage of persons with diagnosed HIV who are virally

suppressed to at least 80%.

4. Increase the percentage of youth (aged 13 – 24 years) and persons who inject

drugs with diagnosed HIV who are virally suppressed to at least 80%.

NYS values for linkage, retention and HIV viral suppression are presented in this report and

compared to the 2020 NHAS targets. “Continuous care” is used synonymously with “retained in

care” and “linkage to care” is used synonymously with “entry to care” in this report.


The Ending the Epidemic initiative set targets for select measures of care by the end of 2020.

The 2020 targets for linkage to care and viral suppression are:

1. Increase the percentage of newly diagnosed persons linked to HIV medical care

within one month of HIV diagnosis to at least 90%.

2. Increase the percentage of persons with diagnosed HIV who are virally

suppressed to at least 85%.

New York State Methods for Counting Persons Living with Diagnosed HIV

Residence in NYS is based on the most recent address reported to the NYS HIV Surveillance

System, regardless of the residency of the individual at diagnosis. Persons diagnosed with HIV

who are a resident outside of NYS but whose most recent address reported to the HIV

surveillance system is in NYS were included in the estimates. Individuals diagnosed in NYS

whose most recently reported address indicated residence outside NYS were excluded.

In addition, individuals whose last reported test to the surveillance system was at least 5 years

(AIDS cases) or 8 years (HIV non-AIDS cases) before December 2016 were not included in the

count of living cases or in estimates of care and viral suppression. These persons are presumed to

be either no longer living or no longer a resident of NYS.

New York State Results

The sections that follow present estimates of engagement in care and viral suppression in NYS.

These estimates are based on data from the NYS HIV Surveillance System following methods

specified by the CDC. The Technical Notes and Appendices provide detailed tables and

explanations of methods and data sources. Caution is advised in comparing cascade outcomes

from different sources. Measures presented by different sources may be calculated differently or

use different information even though their titles are similar. In addition, measures used in

Cascades from the same data source but created at different time points may use different

definitions.


New York State HIV Care Outcome Measures

Linkage to Care after Diagnosis (Appendix Table A)

75% of newly diagnosed cases showed evidence of entry to care within 30 days of

diagnosis and 87% showed evidence of entry to care within 91 days of diagnosis.

Linkage to Care within 30 days of diagnosis

Variable Observation

Region Same for ROS and NYC (75%, respectively);

Lowest in the Buffalo (66%) Ryan White region (RWR);

Highest in the Rochester (89%) RWR

Sex Females (71%) < Males (76%)

Race/Ethnicity Non-Hispanic, White (80%) > Asian/Pacific Islander (76%) > Hispanic

(75%) > Non-Hispanic, Black and Multi Race (73%, respectively)

Age Lowest for ages 25-29 and 50-59 (73%, respectively); Highest for ages 13-

19 years (78%)

Transmission

Risk

MSM/IDU (83%) > MSM (78%) > Heterosexual and IDU (72%,

respectively)

Linkage to Care within 91 days of diagnosis


Region ROS (88%) > NYC (86%);

Lowest in the Binghamton (78%) RWR;


Sex Females (83%) < Males (88%)

Race/Ethnicity Multi Race (92%) > Non-Hispanic, White (90%) > Hispanic (87%) >

Asian/Pacific Islander (86%) > Non-Hispanic, Black (84%)

Age Lowest for ages 50-59 years (85%); Highest for ages 13-19 years (90%)

Transmission

Risk

MSM/IDU (91%) > MSM (90%) > IDU (89%) > Heterosexual (84%)


Measures of Care (Appendix Table B)4

80% of PLWDH showed evidence of some care during the year.

Continuous care (≥2 laboratory tests/year, separated by ≥91 days) was observed for 66%

of PLWDH.

Any Care


Region NYC (82%) > ROS (76%);

Lowest in the Mid-Hudson (73%) RWR;


Sex Females (82%) > Males (80%)

Race/Ethnicity Multi Race (84%) > Hispanic (81%) > Non-Hispanic, Black (80%) > Non-

Hispanic, White (79%) > Asian/Pacific Islander (78%) > Native American

(63%)

Age Lowest for ages 30-39 years (75%); Highest for ages 13-19 years (86%)

Transmission

Risk

IDU (83%) > MSM/IDU and Heterosexual (82%, respectively) > Pediatric

(81%) > MSM (80%)

Continuous Care


Region NYC (67%) > ROS (60%);



Sex Females (68%) > Males (65%)

Race/Ethnicity Hispanic (69%) > Multi Race (68%) > Non-Hispanic, Black and

Asian/Pacific Islander (65%, respectively) > Non-Hispanic, White (62%) >

Native American (47%)

Age Lowest for ages 25-29 years and 30-39 years (57%, respectively); highest

for ages 13-19 years (73%)

Transmission

Risk

IDU (71%) > MSM/IDU (68%) > Heterosexual (67%) > Pediatric and MSM

(64%, respectively)

4 The continuity of care and viral suppression percentages may be underestimates, since laboratory tests performed

in federal facilities, e.g. VA hospitals, and in clinical trials are not comprehensively reported to the state.


Viral Suppression (Appendix Table C)

70% of PLWDH in NYS were virally suppressed, defined as having non-detectable viral

load or a viral load <200 copies/ml at the last test during the year.

Viral Suppression


Region ROS (68%) < NYC (70%);


Highest in Rochester (72%) RWR

Sex Same for men and women (70%, respectively)

Race/Ethnicity Asian/Pacific Islanders (75%) > Non-Hispanic, White (74%) > Multi Race

(72%) > Hispanic (70%) > Non-Hispanic, Black (66%) > Native American

(51%)

Age Lowest among 20-24 years (58%); Highest among those aged 60+ years

(77%)

Transmission

Risk

MSM (72%) > Heterosexual (70%) > IDU (69%) > MSM/IDU (68%) >

Pediatric (56%)


New York State and the NHAS Targets

Linkage to Care

In 2016, the percentage of people in NYS who were newly diagnosed with HIV and entered care

within 30 days of diagnosis (75%) was comparable to the 2016 NYS ETE target of 78%. The

2020 NHAS target is 85% and the 2020 NYS ETE target is 90%.

Continuous Care

In 2016, 66% of PLWDH in NYS had continuous HIV care. This was below the 2020 NHAS

target (90%).

Viral Suppression

New York State’s 70% of PLWDH who appear to be virally suppressed in 2016 is substantially

lower than the 2020 NHAS target (80%) and the 2020 NYS ETE target (85%). In addition,

slightly more than half (59%) of youth (aged 13-24 years) and two-thirds (69%) of people with

injection drug use as the HIV transmission risk appeared to be virally suppressed.

Increasing Linkage and Retention in Care

The NYSDOH aims to increase the number of individuals linked and retained in HIV care by: 1)

identifying persons who are newly diagnosed or PLWDH who are not in HIV care; and 2)

linking these individuals to HIV medical care. Also, as part of the annual HIV Quality of Care

Program Review, organizations that diagnose and treat individuals with HIV in NYS will be

expected to submit cascades reflecting care outcomes among persons newly diagnosed and

currently receiving HIV care.


Technical Notes and Appendices

Contact Information

Please direct inquiries about these measures of HIV health care in NYS to:

Bureau of HIV/AIDS Epidemiology

AIDS Institute, NYSDOH

Empire State Plaza

Albany New York 12237

518-474-4284

[email protected]

Data sources for calculation of HIV care measures

Laboratory data used in these analyses are from the NYS HIV Surveillance System. NYS Public

Health law requires the electronic reporting to the NYSDOH any laboratory test, tests or series of

tests approved for the diagnosis or periodic monitoring of HIV. This includes reactive initial HIV

immunoassay results, all results (e.g. positive, negative, indeterminate) from supplemental HIV

immunoassays (HIV-1/2 antibody differentiation assay, HIV-1 Western blot, HIV-2 Western blot

or HIV-1 Immunofluorescent assay), all HIV nucleic acid (RNA or DNA) detection test results

(qualitative and quantitative; detectable and undetectable), CD4 lymphocyte counts and

percentages, positive HIV detection tests (culture, antigen), and HIV genotypic resistance

testing. Exempted from this rule are tests done for insurance purposes or in clinical trials or in

Federal facilities such as military sites or by the Veterans’ Administration, though several

exempted facilities report in “the spirit of cooperation.” Laboratory data are reported

electronically to NYSDOH, which receives around 1.3 million HIV laboratory reports annually.

Counts of PLWDH were derived from the BHAE statewide analysis file of September 2017.

Counts shown in tables and figures may differ. The percentages for PLWDH shown in report

tables are based on persons who were diagnosed prior to the calendar year and lived to the end of

that year. Data shown in report figures are based on all persons living with diagnosed HIV

regardless of when diagnosed.

Persons living with diagnosed HIV residing in NYS at the end of 2016

Residence in NYS is based on the most recent address reported to the NYS HIV Surveillance

System, regardless of where the individual was diagnosed. For this report, residence is classified

in two ways: 1) living in New York City (NYC); and 2) living in NYS, outside of NYC [Rest of

State (ROS)]. Individuals diagnosed outside NYS but presumed to be residing within the state

(n=7,650), based on the most recent address, were included in the NYS calculations. Individuals

diagnosed within NYS whose most recent address indicated residence outside of NYS were

excluded (n=~3,250).

mailto:[email protected]


Individuals whose last reported test to the surveillance system was at least 5 years (AIDS cases)

or 8 years (HIV non-AIDS cases) before December 2016 were not included in the count of living

cases or in estimates of continuity of care and viral suppression. These persons are presumed to

be either no longer living or no longer residing in NYS (n=~25,900).

Calculation of NYS Cascade measures

1. Estimated HIV persons

CDC’s national estimate (15%) for 2014 was applied to PLWDH residing in NYS, outside

of NYC. An estimate of 5% was applied to PLWDH residing in NYC. Overall, the

combined percentage unaware for NYS in 2016 was 7% (N=9,000).

2. Persons living with diagnosed HIV

NYS uses methodology from the CDC to calculate the cascade measures. Therefore, total

number of PLWDH (Tables B and C) will be different from the number of PLWDH in the

cascade and other NYS reports. The CDC methodology for counting PLWDH: 1) excludes

those <12 years old; and 2) persons must be diagnosed with HIV the previous year (i.e.,

December 2015), and alive at the end of the analysis year (i.e., December 2016).

3. Cases with any HIV care during the year

80% of living cases who were diagnosed and living during the entire year had at least one

reported viral load, CD4 or genotype test, regardless of result (Table B). This percentage

was applied to the entire number of PLWDH as of December 2016.

4. Cases with continuous care during the year

66% of living cases who were diagnosed and alive during the entire year had at least two

laboratory tests (VL, CD4 or genotype) during the year which were separated by at least

91 days (Table B). This percentage was applied to the entire number of PLWDH as of

December 2016.

5. Virally suppressed at test closest to end-of-year

Overall, viral load results were received for 80% of PLWDH who were diagnosed and

alive at the end of 2016. Of those with a viral load test result, 87% had a viral load of

<200 copies/ml or below a quantifiable detection limit at the test closest to end-of-year;

70% of living cases were virally suppressed. This percentage (70%) was applied to the

entire number of PLWDH as of December 2016.


Identification of incarcerated individuals

In counties with relatively low HIV rates among non-incarcerated persons, inclusion of diagnosis

and prevalence data from individuals in state correctional facilities may overstate HIV diagnoses

and prevalence. To address this problem, individuals identified as currently incarcerated in NYS

correctional facilities outside NYC at the end of 2016 are excluded from Ryan White regional

calculations. Identification may be based on most recent residence reported to the registry, on

information reported from the NYS Department of Corrections and Community Supervision to

the NYS HIV Surveillance System, or on receipt by NYSDOH of a laboratory report referencing

a state correctional facility outside NYC.


Table A: Entry to Care in 20161

Persons Newly Diagnosed with HIV, NYS, 20162

All

Entry within 30

days of dx

Entry within 91

days of dx

Residence at Diagnosis

NYC 2,102 1,570 75% 1,817 86%

ROS 758 568 75% 667 88%

NYS Total 2,860 2,138 75% 2,484 87%

Ryan White Region at Dx3

Albany 81 63 78% 71 88%

Binghamton 23 18 78% 18 78%

Buffalo 98 65 66% 86 88%

Lower Hudson 121 88 73% 106 88%

Mid-Hudson 74 56 76% 64 86%

Nassau/Suffolk 214 154 72% 187 87%

Rochester 63 56 89% 59 94%

Syracuse 66 55 83% 60 91%

Birth Sex

Male 2,237 1,698 76% 1,966 88%

Female 623 440 71% 518 83%

Race/Ethnicity4

Non-Hispanic, White 511 409 80% 462 90%

Non-Hispanic, Black 1,112 807 73% 935 84%

Hispanic 951 709 75% 832 87%

Asian/Pac Islander 126 96 76% 108 86%

Native American 2 1 50% 1 50%

Multi Race 158 116 73% 146 92%

Age at Diagnosis

13-19 107 83 78% 96 90%

20-24 403 305 76% 356 88%

25-29 575 418 73% 494 86%

30-39 755 567 75% 652 86%

40-49 473 359 76% 415 88%

50-59 374 273 73% 319 85%

60+ 173 133 77% 152 88%

Transmission Risk

MSM 1,569 1,224 78% 1,419 90%

IDU 65 47 72% 58 89%

MSM/IDU 47 39 83% 43 91%

Heterosexual 727 523 72% 608 84%

Pediatric 1 1 100% 1 100%

Unknown 451 304 67% 355 79% 1 First viral load, CD4, or genotype test after diagnosis, regardless of result

2 NYS HIV surveillance case and laboratory data as of September 2017

3 Regional figures exclude people incarcerated in state correctional facilities; rates based on

fewer than 25 cases are not statistically reliable

4 High percentage entering care among Multi Race is not reliable and is likely an artifact of

CDC’s algorithm for inferring Multi Race


Table B: Measures of Care in 2016

Persons Living with Diagnosed HIV in Dec. 2015 and Alive in Dec. 2016, NYS1

All Any Care2 ≥2 tests, ≥91 days apart

Residence3

NYC 85,774 69,968 82% 57,565 67%

ROS 24,088 18,389 76% 14,572 60%

NYS Total 109,862 88,357 80% 72,137 66%

Ryan White Region 4

Albany 3,044 2,316 76% 1,790 59%

Binghamton 511 380 74% 309 60%

Buffalo 2,751 2,216 81% 1,669 61%

Lower Hudson 3,759 2,895 77% 2,357 63%

Mid-Hudson 2,107 1,542 73% 1,136 54%

Nassau/Suffolk 5,566 4,335 78% 3,385 61%

Rochester 2,852 2,342 82% 1,922 67%

Syracuse 2,213 1,732 78% 1,419 64%

Birth sex

Male 78,179 62,293 80% 50,593 65%

Female 31,683 26,064 82% 21,544 68%

Race/Ethnicity5

Non-Hispanic, White 22,414 17,690 79% 13,947 62%

Non-Hispanic, Black 44,030 35,252 80% 28,485 65%

Hispanic 35,385 28,799 81% 24,299 69%

Asian/Pacific Islander 1,653 1,291 78% 1,067 65%

Native American 62 39 63% 29 47%

Multi Race 6,183 5,179 84% 4,225 68%

Unknown 135 107 79% 85 63%

Age

13-19 463 398 86% 338 73%

20-24 2,368 1,873 79% 1,454 61%

25-29 6,661 5,103 77% 3,794 57%

30-39 17,282 12,920 75% 9,890 57%

40-49 24,805 19,569 79% 15,708 63%

50-59 36,194 29,911 83% 24,968 69%

60+ 22,082 18,577 84% 15,979 72%

Unknown 7 6 86% 6 86%

Transmission Risk

MSM 44,499 35,689 80% 28,570 64%

IDU 13,502 11,166 83% 9,626 71%

MSM/IDU 3,788 3,123 82% 2,584 68%

Heterosexual 31,442 25,713 82% 21,144 67%

Blood Products 191 168 88% 136 71%

Pediatric Risk 2,157 1,742 81% 1,378 64%

Unknown 14,283 10,756 75% 8,699 61% 1 NYS HIV surveillance case and laboratory data as of September 2017 2 At least 1 viral load, CD4, or genotype test during the year 3 Residence as of December 2016 4 Regional figures exclude people incarcerated in state correctional facilities 5 High percentage of persons with care among Multi Race persons is likely an artifact of CDC’s

algorithm for inferring Multi Race


Table C: Viral Suppression1 in 2016

Persons Living with Diagnosed HIV in Dec. 2015 and Alive in Dec. 2016, NYS2

All ≥1 VL Test during the

year

Virally suppressed at test

closest to end of year

% of

All

% of

tested

% of

All

Residence3

NYC 85,774 69,968 82% 60,096 86% 70%

ROS 24,088 18,389 76% 16,493 90% 68%

NYS Total 109,862 88,357 80% 76,590 87% 70%

Ryan White Region 4

Albany 3,044 2,316 76% 2,078 90% 68%

Binghamton 511 380 74% 335 88% 65%

Buffalo 2,751 2,216 81% 1,932 87% 70%

Lower Hudson 3,759 2,895 77% 2,618 90% 70%

Mid-Hudson 2,107 1,542 73% 1,354 88% 64%

Nassau/Suffolk 5,566 4,335 78% 3,958 91% 71%

Rochester 2,852 2,342 82% 2,063 88% 72%

Syracuse 2,213 1,732 78% 1,574 91% 71%

Birth sex

Male 78,179 62,293 80% 54,492 87% 70%

Female 31,683 26,064 82% 22,098 85% 70%

Race/Ethnicity5

Non-Hispanic, White 22,414 17,690 79% 16,632 94% 74%

Non-Hispanic, Black 44,030 35,252 80% 29,255 83% 66%

Hispanic 35,385 28,799 81% 24,887 86% 70%

Asian/Pacific Islander 1,653 1,291 78% 1,238 96% 75%

Native American 62 39 63% 31 81% 51%

Multi Race 6,183 5,179 84% 4,443 86% 72%

Unknown 135 107 79% 103 97% 77%

Age

13-19 463 398 86% 299 75% 65%

20-24 2,368 1,873 79% 1,371 73% 58%

25-29 6,661 5,103 77% 4,040 79% 61%

30-39 17,282 12,920 75% 10,739 83% 62%

40-49 24,805 19,569 79% 16,720 85% 67%

50-59 36,194 29,911 83% 26,371 88% 73%

60+ 22,082 18,577 84% 17,045 92% 77%

Unknown 7 6 86% 5 84% 72%

Transmission Risk

MSM 44,499 35,689 80% 31,860 89% 72%

IDU 13,502 11,166 83% 9,333 84% 69%

MSM/IDU 3,788 3,123 82% 2,573 82% 68%

Heterosexual 31,442 25,713 82% 22,157 86% 70%

Blood Products 191 168 88% 147 87% 77%

Pediatric Risk 2,157 1,742 81% 1,210 69% 56%

Unknown 14,283 10,756 75% 9,309 87% 65% 1 Virally suppressed defined as viral load non-detectable or <200 copies/ml 2 NYS HIV surveillance case and laboratory data as of September 2017 3 Residence as of December 2016 4 Regional figures exclude people incarcerated in state correctional facilities 5 High percentage of persons with care among Multi Race persons is likely an artifact of CDC’s

algorithm for inferring Multi Race

hiv care in new york state - linkage to care and viral ... · new york state methods for counting...

Documents